This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Data Mining Comes Up Empty

Cel-Sci claims treatment with Multikine led to a statistically significant reduction in cholesterol, but what was their drug compared to for that conclusion to be reached? None of the phase II studies of Multikine conducted by Cel-Sci included a control arm -- meaning all the patients received Multikine. How then, can these studies demonstrate a statistically significant reduction in cholesterol? Cel-Sci doesn't say.

Perhaps Cel-Sci split the Multikine-treated patients into two groups -- those taking statin drugs for high cholesterol and those who were not. Again, Cel-Sci doesn't explain. Of course, it doesn't really matter because we run full circle back to the data-mining problem -- the studies weren't originally designed to split patients into statin and non-statin users.

If the cholesterol-lowering finding from this meta-analysis of Multikine studies is reality challenged, why would Cel-Sci bother with it? The answer goes back to what I warned up top -- positive results derived from post-hoc data mining are usually a smokescreen seeking to cover up other problems.

In Cel-Sci's case that means problems with the ongoing phase III study of Multikine, which is taking forever to get off the ground. The number of press releases issued by Cel-Sci announcing the start of the phase III trial appears to exceed the number of patients actually enrolled. Cel-Sci's problems run deeper still because lackluster Multikine data from the phase II studies gives the drug little chance of succeeding in the phase III study.

Yet Cel-Sci's needs to keep hope alive, lest gullible retail shareholders lose interest and the disbursement of management's annual paychecks become threatened.

Desperate companies like Apricus and Cel-Sci use data dredging as a necessary survival tool. Smart investors recognize the danger signs and steer clear.

Post script: As I was putting this column together, I saw news that Transdel Pharmaceuticals (TDLP) filed for bankruptcy this week and sold off its remaining assets. Transdel was also a data-mining offender.

Fair warning.

More companies guilty of data-mining: Osiris Therapeutics (OSIR - Get Report), Agenus (AGEN - Get Report) (formerly Antigenics), Introgen Therapeutics (defunct, another bankruptcy), and Cell Therapeutics (CTIC - Get Report), which famously re-analyzed a failed lung cancer trial claiming its drug Opaxio (formerly Xyotax) only worked for women.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CTIC $1.81 0.00%
AGEN $4.89 0.00%
APRI $1.91 0.00%
CVM $1.02 0.00%
OSIR $17.69 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs